La chaîne d'options affiche les données clés des options sur actions de Johnson & Johnson à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Johnson & Johnson..

Johnson & Johnson (NYSE:JNJ) Stock, Chaîne d'Options

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

JOHNSON & JOHNSON ORD

The U.S. Trustee Program, a unit of the Department of Justice (DOJ) overseeing bankruptcy cases, has filed a motion in federal bankruptcy court in Houston to dismiss a Chapter 11 filing by a subsidiary of Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>).
The <a target="_blank" href="https://aboutblaw.com/bf1t" rel="noreferrer noopener">filing</a> aims to settle more than 60,000 talc-related lawsuits, marking J&amp;J's third attempt to pursue this strategy in as many years.
In September, Johnson &amp; Johnson reportedly increased its settlement offer by $1 billion, now totaling about $9 billion, to address claims that its talc baby powder&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40738358/johnson-johnson-raises-talc-settlement-offer-to-9b-moves-closer-to-settlement-victory" rel="noreferrer noopener">caused gynecological cancer</a>.
The DOJ argues that Johnson &amp; Johnson's latest bankruptcy maneuver is a bad-faith attempt to shield itself from billions in personal injury claims without actually entering bankruptcy.
The company's approach involves creating a new subsidiary, transferring billions in liabilities but few assets to this entity, and then filing for bankruptcy on its behalf.
This move is seen as a way for Johnson &amp; Johnson to secure a third-party release that would discharge both itself and the subsidiary from liability—an action that was expressly prohibited in a recent Supreme Court ruling.
Johnson &amp; Johnson has used similar tactics in the past, both dismissed due to findings of bad faith.
Despite these setbacks, the company has filed this new case under a different entity and jurisdiction, which the DOJ believes is an attempt to sidestep previous rulings.
The trustee's motion claims that the debtor in question has no valid reason for bankruptcy protection and that the filing serves no legitimate restructuring purpose.
The ongoing litigation stems from numerous claims that Johnson &amp; Johnson's talc-based products, including baby powder, caused personal injuries.
Many lawsuits assert a link between talc exposure and ovarian cancer, while others allege that the products were contaminated with asbestos, leading to mesothelioma.
J&amp;J has consistently denied these allegations.
As of October 2021, around 36,000 ovarian cancer claims and 470 mesothelioma cases were tied to Johnson &amp; Johnson's talc products, with many cases consolidated in a multi-district litigation in New Jersey.
Price Action: JNJ stock closed 0.38% at $163.45 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41463868/kimberly-clarks-growth-potential-underestimated-analyst-sees-attractive-entry-point" target="_blank" rel="noreferrer noopener">Kimberly-Clark's Growth Potential' Underestimated,' Analyst Sees Attractive Entry Point</a></li>
</ul>
Photo via Wikimedia Commons

Biotech

Large Cap

News

Health Care

Legal

General

Justice Department's Trustee Program Alleges Johnson & Johnson's Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid Liability

Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) short percent of float has fallen 14.58% since its last report. The company recently reported that it has 19.74 million shares sold short, which is 0.82% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Johnson &amp; Johnson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729620922_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Johnson &amp; Johnson has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Johnson &amp; Johnson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Johnson &amp; Johnson's peer group average for short interest as a percentage of float is 4.55%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Johnson & Johnson's Recent Short Interest

Kenvue Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) shares are moving higher Monday following a report suggesting activist investor Starboard Value has acquired <a href="https://www.benzinga.com/markets/equities/24/10/41419988/tylenol-listerine-maker-kenvue-under-activist-spotlight-with-starboard-value-stake-overhaul-ahea">a stake in the company</a>. 
The Details: According to the <a href="https://www.wsj.com/business/deals/activist-starboard-value-takes-stake-in-tylenol-maker-kenvue-cc3175bb">Wall Street Journal</a>, Starboard has acquired a &#8220;sizable&#8221; stake in Kenvue and is pushing for changes to boost the consumer-products company&#8217;s share price. The activist investor asserts that Kenvue has &#8220;some of the best consumer brands,&#8221; yet its stock has lagged behind its competitors for over a year.
Kenvue&#8217;s iconic brands include Aveeno, BAND-AID Brand, Johnson&#8217;s, Listerine, Neutrogena and Tylenol. Kenvue shares are up just 7% year-to-date compared to more than 23% gains in the S&amp;P 500. Competitors Haleon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) and Proctor and Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) have climbed 21% and 16%, respectively, since the start of the year.
The exact size of Starboard's position in Kenvue was not shared. Starboard&#8217;s specific turnaround ideas were also not reported, but people familiar with the matter said Starboard CEO Jeff Smith is expected to discuss more about Starboard&#8217;s perspective on Kenvue at the 13D Monitor Active-Passive Investor Summit in New York on Tuesday. 
According to a separate <a href="https://www.msn.com/en-us/money/companies/activist-starboard-could-push-for-kenvue-to-sell-some-all-of-its-sbh-business-analyst/ar-AA1sEH3C?ocid=finance-verthp-feeds">report</a>, Starboard may try to push the company to sell its skin, healthcare and beauty division in whole or part.
In a note released Monday, JPMorgan analyst Andrea Teixeira said, &#8220;Given the SHB segment has been a key area of debate on the stock over the past year and a half, we would expect Starboard to detail changes it would like to see management make to this division — which we suspect could involve divesting some/all of the segment.&#8221;
Kenvue was spun out of Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) last year. The company currently has a market cap of more than $41 billion, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Related Link: <a href="https://www.benzinga.com/news/24/10/41417197/elon-musk-tesla-refute-inefficiency-concerns-with-wireless-charging-on-cybercab-there-is-no-meaningf">Elon Musk, Tesla Refute Inefficiency Concerns With Wireless Charging On Cybercab: &#8216;There Is No Meaningful Efficiency Difference…&#8217;</a>
KVUE Price Action: At the time of publication, Kenvue stock was up 5.96% at $23.02, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: 3972315 from Pixabay.

Movers

KVUE

What's Going On With Kenvue Stock Monday?

Starboard Value, an activist investor, has reportedly acquired a substantial stake in Kenvue Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>), the company behind popular consumer products like Tylenol and Listerine.
What Happened: Starboard Value is pushing for changes at Kenvue, which was spun off from Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) last year and has a market value of over $40 billion, <a href="https://www.wsj.com/business/deals/activist-starboard-value-takes-stake-in-tylenol-maker-kenvue-cc3175bb?mod=breakingnews">reported</a> The Wall Street Journal, citing people familiar with the matter.
Despite having some of the best consumer brands in the industry, Kenvue&#8217;s stock has underperformed its peers and the broader market since its debut over a year ago.
The exact size of Starboard&#8217;s position in Kenvue and its specific ideas for the company are not known. Starboard&#8217;s founder and CEO, Jeff Smith, is expected to present the firm&#8217;s thesis on Kenvue at an activist investing conference in New York on Tuesday.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41372090/anthony-scaramucci-tells-what-percentage-of-his-wealth-is-tied-up-in-bitcoin-i-havent-sold?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Anthony Scaramucci Tells What Percentage Of His Wealth Is Tied Up In Bitcoin: &#8216;I Haven&#8217;t Sold Any. Thank God, Knock On Wood!&#8217;</a>
Kenvue&#8217;s other brands include Aveeno, Band-Aid, Zyrtec, Neosporin, and Neutrogena. The company, led by CEO Thibaut Mongon, recorded over $15 billion in net sales in 2023.
Kenvue and Starboard Value &nbsp;did not immediately respond to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga</a>'s request for comment.
Why It Matters: Kenvue&#8217;s stock price has remained relatively unchanged this year, in contrast to the S&amp;P 500 index&#8217;s 23% increase. The company&#8217;s biggest competitors include Haleon, the parent company of Advil, Procter &amp; Gamble, the owner of Pepto-Bismol, and Unilever, the maker of Axe deodorant.
Starboard&#8217;s recent investment in Kenvue follows its move to acquire a roughly $1 billion stake in Pfizer Inc., where it is seeking various changes to <a href="https://www.benzinga.com/markets/equities/24/10/41264265/former-pfizer-executives-ian-read-and-frank-damelio-support-albert-bourlas-leadership-amid-starb">improve the drugmaker&#8217;s performance</a>. This includes the appointment of former Pfizer executives Ian Read and Frank D&#8217;Amelio, who have pledged their support for current Pfizer CEO Albert Bourla.
Starboard is known for its active <a href="https://www.benzinga.com/markets/equities/24/07/39785537/tinder-parent-match-group-soars-nearly-9-in-after-hours-trading-as-activist-hedge-fund-starboard">involvement in various sectors</a>, including technology, where it has recently made efforts at companies like Salesforce, Autodesk, and Match Group.
Price Action: Kenvue Inc.&#8217;s stock closed at $21.72 on Friday, up 1.26% with a gain of $0.27. Year to date, the stock has risen by 0.70%, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/esg/24/10/41409688/this-small-cap-nuclear-stock-is-up-over-100-in-a-month-will-it-keep-generating-momentum?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">This Small-Cap Nuclear Stock Is Up Over 100% In A Month: Will It Keep Generating Momentum?</a></li>
</ul>
Image Via Shutterstock 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Equities

Markets

Tylenol, Listerine Maker Kenvue Under Activist Spotlight With Starboard Value Stake — Overhaul Ahead For The Johnson & Johnson Spinoff?

In a year and a half, Eli Lilly (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) has roughly <a href="https://www.marketbeat.com/stocks/NYSE/LLY/chart/">doubled in value</a>. It is now the most valuable <a href="https://www.marketbeat.com/compare-stocks/pharmaceutical-stocks/">pharmaceutical company</a> in the world. It took that mantle from the long-held dominance by <a href="https://www.marketbeat.com/stocks/NYSE/JNJ/">Johnson and Johnson (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>) back in May of 2023 and hasn&#39;t looked back since. However, much of that increase in value has come due to multiple expansions; the market is now paying more for every dollar of the company&#39;s earnings.
Revenues at Johnson and Johnson are still over double those of Eli Lilly over the last twelve months. Looking at net income, the relationship is similar. Compared to the beginning of May 2023, investors have now accepted paying around 2.8 times more for each dollar of earnings Eli Lilly has already generated. But, investors are paying around 40% less for each dollar of already generated J&amp;J earnings.
However, the stock market largely attributes value to a company based on its ability to generate earnings in the future. Based on Lilly&#39;s next twelve months forward P/E ratio, investors are paying about the same now for each dollar of future earnings as they were in May of 2023.
The gap between the backward-looking P/E and the forward-looking P/E suggests a belief that the company&#39;s earnings will rise strongly in the future. This would align its true earnings power with the stock price. In order to justify this, Lilly&#39;s earnings need to continue rising strongly in line with expectations. I will detail how the company plans to do this. I will also discuss potential catalysts that could help it exceed its high expectations.
<h3>Eli Lilly Is Growing Fast And Continues To Innovate</h3>
Much of the company&#39;s increase in value has come from intense excitement over its weight loss and diabetes drugs. Specifically, Zepbound and Mounjaro have experienced rapid sales growth. The former grew sales by 140% in just one quarter, based on the latest financial results. The older Mounjaro saw sales rise 72%. Although this growth is very impressive, the company needs to continue innovating to stay ahead of the game. Many smaller firms have seen the massive demand developing for these drugs over the years and are working on treatments to take a slice of the pie.
Lilly is pursuing an <a href="https://clinicaltrials.gov/study/NCT06440980?intr=Orforglipron&amp;rank=1">oral weight loss drug</a>. Other companies are doing this too, but Lilly&#39;s drug is comparatively further along than many others. The company could release Phase 3 Food and Drug Administration (FDA) results in mid to late 2025.
In contrast, Novo Nordisk (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvo#NYSE">NVO</a>) recently released Phase 2 and Phase 1 results for oral weight loss treatments, which delays their potential timeline to market. This could allow the company to take on significant initial growth based on its already established reputation and first-mover advantage for patients who want this version of the drug.
The company also announced a <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-announces-new-45-bln-manufacturing-site-indiana-2024-10-02/#:~:text=The%20facility%2C%20Lilly%20Medicine%20Foundry,to%20open%20in%20late%202027.">$4.5 billion investment</a>. It will build a new factory to ramp up production of unapproved drugs. This will allow it to hit the ground running if the drugs get approved.
<h3>Lilly Is Fighting Back Against Copycats And Expanding Its Market</h3>
Lilly also <a href="https://www.youtube.com/watch?v=6qtHRa-oxCA">recently began a program</a> where patients can directly purchase Zepbound for 50% less than the normal price from the company. However, patients can make these purchases with cash only; they cannot use insurance coverage. Zepbound is designed to treat obesity, not diabetes. So, many insurance plans do not cover it. This includes Medicare, the largest payer of healthcare services in the country.
This expands the market that the company can sell to and helps the firm fight back against unauthorized copycat distributors of the drug. It also provides some help to the company&#39;s inability to keep up with demand for its drug. It comes in a vial rather than an injectable pen. Not being able to make enough pens has been a key source of the undersupply.
On Oct. 3, the FDA removed Zepbound and Mounjaro <a href="https://www.fiercepharma.com/pharma/eli-lillys-shortage-glp-1-drugs-over-halting-competition-knock-offs">from its drug shortage list</a>, another positive sign. Additionally, Lily doesn&#39;t have all its eggs in the weight loss and diabetes market. These drugs made up 66% of revenue last quarter, but its two other largest treatment areas are also growing solidly. Immunology revenue increased by 30%, and oncology revenue increased by 20% last quarter.
<h3>Lilly Can Stay Top Dog</h3>
Overall, I am impressed by Lily&#39;s ability and willingness to find innovative solutions and stay ahead of the curve. I believe this bodes well for the future of the company and that the firm will continue to stay at the top of the heap in pharmaceuticals.
The article &quot;<a href="https://www.marketbeat.com/originals/why-eli-lilly-stock-is-soaringand-how-it-plans-to-stay-on-top/">Why Eli Lilly Stock Is Soaring&mdash;and How It Plans to Stay on Top</a>&quot; first appeared on MarketBeat.

Why Eli Lilly Stock Is Soaring—And How It Plans To Stay On Top

BofA Securities has upgraded Tyra Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>), a clinical-stage biotechnology company focused on&nbsp;developing next-generation precision medicines.
The company&#8217;s <a target="_blank" href="https://tyra.bio/pipeline/" rel="noreferrer noopener">initial</a> focus is on improving small molecule drug discovery and development in targeted oncology and genetically defined conditions.
The company has a pipeline of four preclinical candidates. In July, Tyra Biosciences announced preclinical proof-of-concept results with TYRA-300 in hypochondroplasia (HCH), the most <a href="https://www.benzinga.com/pressreleases/24/07/n39605869/tyra-biosciences-announces-preclinical-proof-of-concept-results-with-tyra-300-in-hypochondroplasia" target="_blank" rel="noreferrer noopener">common form of dwarfism</a>.
TYRA-300 increased the length of the appendicular skeleton in the FGFR3 mutated mice: the femur by 3.70% compared to the vehicle, the tibia by 3.75%, the humerus by 3.22%, and the ulna by 5.03%.
TYRA-300 also increased the size of the foramen magnum by 5.88% (p&lt;0.05) in mice. TYRA-300 demonstrated binding against the FGFR3 N540K altered protein and isoform selectivity for FGFR3 over other isoforms.
BofA has upgraded Tyra Biosciences from Neutral to Buy with a price target <a target="_blank" href="https://www.benzinga.com/quote/TYRA/analyst-ratings" rel="noreferrer noopener">of $31, up from $22</a>, ahead of the upcoming presentation of the phase 1/2 SURF-301 of TYRA-300 for urothelial carcinoma/ solid tumors at the ENA Meeting next week.
The analyst suggests that while Johnson &amp; Johnson&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) erdafitinib may have established a high efficacy benchmark, its poor tolerability has significantly limited its use.
&#8220;To that end, we think the bar for success for &#8216;300 is safety vs. efficacy,&#8221; BofA analyst writes.
The updated model reflects greater potential uptake of an FGF3R-inhibitor with a differentiated safety profile while increasing the likelihood of success (LoS) risk adjustment to 35% from 15% prior in mUC.
The analyst projects 2030 adjusted sales for metastatic urothelial carcinoma to reach $175 million, up from a previous estimate of $35 million, compared to the consensus of $182 million.
The analyst highlights that Tyra Biosciences stock had a strong year (YTD +89% vs. +10% NBI)
Price Action: TYRA stock is up 3.77% at $26.96 at last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41407594/europe-drug-regulators-advising-panel-recommends-approval-of-novo-nordisks-australia-approved-hem" target="_blank" rel="noreferrer noopener">Europe Drug Regulator&#8217;s Advising Panel Recommends Approval Of Novo Nordisk&#8217;s Australia-Approved Hemophilia Drug</a>.</li>
</ul>

Analyst Color

Upgrades

Price Target

Analyst Ratings

TYRA

BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug

Investors with a lot of money to spend have taken a bearish stance on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with JNJ, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Johnson &amp; Johnson.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 50%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $104,000, and 7, calls, for a total amount of $338,554.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $160.0 to $180.0 for Johnson &amp; Johnson over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Johnson &amp; Johnson's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Johnson &amp; Johnson's substantial trades, within a strike price spectrum from $160.0 to $180.0 over the preceding 30 days.
<h3>Johnson &amp; Johnson Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729269040_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.63</td>
<td>$2.4</td>
<td>$2.6</td>
<td>$165.00</td>
<td>$104.0K</td>
<td>2.3K</td>
<td>481</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$3.1</td>
<td>$2.3</td>
<td>$3.0</td>
<td>$165.00</td>
<td>$60.0K</td>
<td>7.9K</td>
<td>0</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.05</td>
<td>$2.97</td>
<td>$2.97</td>
<td>$165.00</td>
<td>$59.4K</td>
<td>7.9K</td>
<td>1.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.2</td>
<td>$2.85</td>
<td>$2.93</td>
<td>$165.00</td>
<td>$58.5K</td>
<td>7.9K</td>
<td>404</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$2.94</td>
<td>$2.9</td>
<td>$2.94</td>
<td>$165.00</td>
<td>$51.4K</td>
<td>7.9K</td>
<td>855</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
After a thorough review of the options trading surrounding Johnson &amp; Johnson, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Johnson &amp; Johnson</h3>
<ul>
<li>Currently trading with a volume of 1,877,656, the JNJ's price is up by 0.27%, now at $164.92. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 95 days.</li>
</ul>
<h3>What The Experts Say On Johnson &amp; Johnson</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $201.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $215. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $215. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Johnson &amp; Johnson with a target price of $175. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $215. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Johnson &amp; Johnson, maintaining a target price of $185. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Johnson &amp; Johnson options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Johnson & Johnson Unusual Options Activity

Johnson &amp; Johnson&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>) stock price advance has been reinvigorated. The stock price rally stalled a few years ago due to the COVID-19 bubble bursting and the divestiture of Kenvue (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kvue#NYSE">KVUE</a>), but those days are behind, and business growth is still ahead. Today, Johnson &amp; Johnson is a buy because its value, yield, and growth outlook provide a vehicle capable of market-beating returns in 2025 and over the long term.&nbsp;
Regarding value, this healthcare stock is trading at 16x this year&#39;s earnings, less than half the historical average price multiple and well below the S&amp;P 500 average. Regarding returns, Johnson &amp; Johnson is a reliable dividend payer yielding more than 3%, more than double the broad market average, and at the high end of the historical range with a solid outlook for sustained distribution increases over the next few years.&nbsp;
<h2>Johnson &amp; Johnson Turns a Corner in Q3 2024</h2>
Johnson &amp; Johnson turned a corner in Q3 2024 with operational growth resulting in reported growth as comps to the COVID and pre-spinoff periods lapse. Reported growth is expected to continue in Q4 and next year, accelerating in 2025.&nbsp;
Regarding Q3, the company reported a 5.2% YoY increase in revenue driven by strengths in both operational regions and segments. Operational growth was more robust at 6.3% and 5.4% adjusted for COVID-19, with U.S. sales up by 7%, leading International&#39;s 4.6% growth and growth even near 6.35% in the Internal Medicine and Medical Technology segments. Internal Medicine and MedTech are driven by sustained strengths in existing treatments compounded by new approvals and product launches during the quarter.&nbsp;
The margin news is mixed but favorable to investors. Acquisitional costs, including acquired IPRD expenses, impacted GAAP and adjusted profits, but much less than expected. Because of this, GAAP and adjusted EPS, including IPRD costs, were contracted, but the impact of IPRD is worth 1900 basis points and is more than sufficient to offset the decline. Adjusted EPS is also 950 basis points better than expected.
The guidance is also mixed but favorable to shareholders. The company raised its guidance for revenue due to organic strength and the impact of the V-Wave acquisition but trimmed its target for earnings. The takeaway is that revenue is forecast above the consensus analysts&#39; target, the impact of the acquisition on earnings will diminish, and earnings are sufficient to sustain the capital return program, which is robust. The healthy dividend is compounded by share repurchases, which reduced the count by 4.7% in the quarter and 6.6% compared to last year.&nbsp;
<h2>Institutions Signal the Floor for Johnson &amp; Johnson Is $145</h2>
Institutional and analyst activity has been mixed over the last year, with intermittent selling periods and numerous negative revisions. However, institutional buying in 2024 coincides with price rebound in Q1 and Q3, which show solid support at the $145 level, which coincides with the low end of the analysts&#39;&nbsp;target range. Institutional activity could provide a tailwind in Q4 because activity in the first weeks remains bullish on balance.
Analyst activity is also shifting toward a more bullish bias. The activity in early October includes two reiterated Outperform ratings with price targets above the consensus reported by MarketBeat.com. The consensus of $175 implies a 5% upside and is rising in Q3 compared to last year and last quarter, with the upside range adding another $40 or nearly 25%.&nbsp;
The technical outlook is bullish. The market for JNJ stock is range-bound within a multiyear range but moving upward within it. The latest activity shows the market in rally mode and consolidating beneath a critical uptrend line, setting up to move higher over the coming weeks. Assuming the market follows through on the signal, JNJ could hit the top of the range near $180 by early 2025.&nbsp;
<img alt="Johnson &amp; Johnson JNJ stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20241015124542_chart-jnj-10152024.png" style="height:446px; width:917px" />
The article &quot;<a href="https://www.marketbeat.com/originals/johnson-and-johnson-stock-setting-the-stage-for-2025-highs/">Johnson &amp; Johnson Stock: Setting the Stage for 2025 Highs</a>&quot; first appeared on MarketBeat.

Earnings

Guidance

Dividends

Technicals

Johnson & Johnson Stock: Setting the Stage for 2025 Highs

Citigroup analyst Joanne Wuensch maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Buy and raises the price target from $180 to $185.

Citigroup Maintains Buy on Johnson & Johnson, Raises Price Target to $185

On Tuesday,&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)&nbsp;reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.21</a>. The pharmaceutical giant reported sales of $22.47 billion, up 5.2% year over year and beating the consensus&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41329767/johnson-johnsons-q3-earnings-revenue-and-eps-beat-on-strong-cancer-drug-sales-revises-annual-outl" rel="noreferrer noopener">of $22.16 billion</a>.
Johnson &amp; Johnson updated the full-year 2024 adjusted operational EPS guidance to reflect improved performance and the acquisition of V-Wave; the costs associated with the acquisition more than&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40464864/johnson-johnson-strikes-1-7b-deal-to-acquire-heart-tech-innovator-v-wave" rel="noreferrer noopener">offset the improvement</a>.
BofA Securities reiterates a Neutral rating and a <a target="_blank" href="https://www.benzinga.com/quote/JNJ/analyst-ratings" rel="noreferrer noopener">price target of $170</a>. The analyst projects the Oncology franchise will maintain strong performance next year, with Darzalex and Carvykti expanding their market share globally in first—and second-line+ treatments for multiple myeloma.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41189182/johnson-johnson-ends-phase-2-study-for-dengue-antiviral-amid-r-d-reprioritization" rel="noreferrer noopener">Johnson &amp; Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&amp;D Reprioritization</a>.
The analyst also anticipates a boost in Rybrevant sales for EGFR+ lung cancer following the approval and launch of its subcutaneous formulation in the first half of 2025.
Additionally, Tremfya is expected to post over 20% year-over-year growth, driven by ongoing launches for inflammatory bowel disease.
In contrast, Stelara could rapidly decline by around 25% as biosimilars enter the U.S. market in January 2025.
Meanwhile, the MedTech segment will likely encounter challenges due to volume-based procurement pressures.
The outcome of the talc litigation remains uncertain. U.S. courts will decide whether Johnson &amp; Johnson can use bankruptcy proceedings to resolve current and future claims.
Needham reports that while Johnson &amp; Johnson saw a slight slowdown in organic MedTech growth in Q3 2024 compared to Q2, with sales falling about 2% below consensus, the analyst attributes this to specific company factors.
These include a higher exposure to the Chinese market, the Orthopedics Transformation program, and competitive pressures.
Management also highlighted potential headwinds in Q4 2024 due to recent hurricanes but expressed greater concern over the shortage of IV solutions than the direct impact of the storms on procedures.
Overall, the analyst views Johnson &amp; Johnson&#8217;s performance as neutral for most of the med tech sector.
Price Action: JNJ stock is up 0.15% at $164.34 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41360197/gsk-seeks-fda-approval-for-oral-antibiotic-for-urinary-tract-infections-probably-first-in-new-cla" target="_blank" rel="noreferrer noopener">GSK Seeks FDA Approval For Oral Antibiotic For Urinary Tract Infections, Probably First In New Class In Over 20 Years</a></li>
</ul>
Photo by Tada Images via Shutterstock

Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say

Wells Fargo analyst Larry Biegelsen maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Equal-Weight and raises the price target from $163 to $166.

Wells Fargo Maintains Equal-Weight on Johnson & Johnson, Raises Price Target to $166

Cantor Fitzgerald analyst Louise Chen reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Overweight and maintains $215 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target

RBC Capital analyst Shagun Singh maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Outperform and raises the price target from $178 to $181.

RBC Capital Maintains Outperform on Johnson & Johnson, Raises Price Target to $181

Morgan Stanley analyst Terence Flynn maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Equal-Weight and raises the price target from $169 to $175.

Morgan Stanley Maintains Equal-Weight on Johnson & Johnson, Raises Price Target to $175

The jury awarded&nbsp;$15 million&nbsp;in compensatory damages and answered in the affirmative that punitive damages were justified, meaning the ultimate verdict amount could go higher. J&amp;J subsidiaries Kenvue, Holdco, Pecos River, LLT, and LTL also were defendants in the lawsuit.

Reported Earlier, Johnson & Johnson Ordered To Pay $15M In Connecticut Asbestos Case, Facing Potential For Punitive Damagesjnj

J&Js Talc Powder Is Responsible For Connecticut Man's Cancer, Jury Finds

On Tuesday, Johnson &amp; Johnson (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>) posted better-than-expected third quarter sales and adjusted profit. Fueled by strong results, Johnson &amp; Johnson raised its full year profit and sales guidance. Also on Wednesday, the&nbsp;struggling pharmacy chain operator, Walgreens Boots Alliance Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wba#NASDAQ">WBA</a>) announced it will be shutting down 1,200 of its stores.&nbsp;Under the new leadership of Tim Wentworth, WBA has embarked on a turnaround journey amid a challenging climate shaped by sluggish consumer spending and low drug reimbursement rates.
<h3>Third Quarter Highlights</h3>
For the quarter ended in September, the pharmaceutical and medical device company&nbsp;posted sales&nbsp;of $22.47 billion,&nbsp;implying a YoY growth of 5.2%.&nbsp;
Medical devices unit reported sales grew 5.8% to $7.9 billion, but MedTech had faced &ldquo;headwinds&rdquo; in the form of economic slowdowns in China and Japan, as well as a physician&rsquo;s strike in Korea.
Across the globe, J&amp;J&#39;s cancer drugs rose nearly 19%,&nbsp;led by more than $3 billion for multiple myeloma treatment Darzalexwhose sales grew 20.7% YoY due to regulatory approval for additional uses.&nbsp;CFO&nbsp;Joe Wolk&nbsp;said that the continued adoption of the subcutaneous version of Darzalex has been shown to significantly reduce treatment time.&nbsp;Cancer cell therapy, Carvykti, brought in sales of $286 million.
On the other hand, its&nbsp;blockbuster psoriasis drug Stelara postes a revenue drop of 6.6% as sales amounted to $2.68 billion, with sales expected to fall further next year with as many as&nbsp;six biosimilar competitors in the U.S.&nbsp;
Due to one-time expenses including acquisitions and legal costs, net income tanked 38% to $2.69 billion. But although adjusted earnings dropped 9% YoY to $2.42 per share, they still topped LSEG&rsquo;s consensus estimate of&nbsp;$2.21&nbsp;per share.&nbsp;
<h3>An Outlook Boost</h3>
The New Jersey-based healthcare conglomerate&nbsp;lifted its full year outlook. While Johnson and Johnson previously expected to post full year sales between&nbsp;$89.2 billion and $89.6 billion, it now guided for a range between $89.4 billion and $89.8 billion. Including one-time charges related to mergers and acquisitions, Johnson &amp; Johnson expects full year earnings to be between $9.86 and $9.96 per share, having tweaked its prior estimate due to&nbsp;improved performance outlook&nbsp;that was offset by a charge from its latest acquisition that closed last week, concerning the privately-held medical technology company V-Wave
Despite Stelara&#39;s loss of exclusivity, J&amp;J remains confident it can post 2025 pharmaceutical sales above its $57 billion target.
Although talc ligitation concerns remain as a cloud over its long-term picture, Johnson &amp; Johnson has atleast eased worries when it comes to its current business&nbsp;and&nbsp;financial performance.
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Cancer Drugs Propel J&J Beyond Wall Street Estimates

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 150 points on Tuesday.
The Dow traded down 0.30% to 42,937.44 while the NASDAQ fell 0.84% to 18,347.17. The S&amp;P 500 also fell, dropping, 0.43% to 5,834.67.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/10/41331971/how-to-earn-500-a-month-from-morgan-stanley-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Morgan Stanley Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Real estate shares jumped by 2% on Tuesday.
In trading on Tuesday, energy shares fell by 2.3%.
Top Headline
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) reported upbeat results for its third quarter.
The company posted adjusted EPS of $2.42, down 9.0% year-over-year, beating the consensus of $2.21. The pharmaceutical giant reported sales of $22.47 billion, up 5.2% year over year and beating the consensus of $22.16 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares shot up 21% to $13.78 after the company announced it signed a signed a non-binding preliminary memorandum of terms for up to $750 million in proposed direct funding under the CHIPS and Science Act.</li>
<li>Shares of MeiraGTx Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGTX#NASDAQ">MGTX</a>) got a boost, surging 14% to $5.28 after safety and tolerability was confirmed in its gene therapy study for Parkinson&#8217;s.</li>
<li>Telefonaktiebolaget LM Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) shares were also up, gaining 13% to $8.56 following a third-quarter earnings beat.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Seelos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares dropped 43% to $1.4050. Seelos Therapeutics announced notice of delisting from Nasdaq and transfer of listing to Over-the-Counter Market.</li>
<li>Shares of CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) were down 14% to $26.85 as the company reported preliminary results for the third quarter.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) was down, falling 14% to $0.1070 after the company announced a 1-for-50 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded down 4.5% to $70.54 while gold traded up 0.4% at $2,676.80.
Silver traded up 1.2% to $31.69 on Tuesday, while copper fell 1.6% to $4.3360.
Euro zone
European shares closed mostly lower today. The eurozone's STOXX 600 slipped 0.80%, Germany's DAX slipped 0.11% and France's CAC 40 fell 1.05%. Spain's IBEX 35 Index rose 0.67%, while London's FTSE 100 fell 0.52%.
Asia Pacific Markets
Asian markets closed mostly lower on Tuesday, with Japan's Nikkei 225 gaining 0.77%, Hong Kong's Hang Seng Index falling 3.67%, China's Shanghai Composite Index dipping 2.53% and India's BSE Sensex falling 0.19%.
Economics
The NY Empire State Manufacturing Index declined to -11.9 in October from 11.5 in the previous month and topping market estimates of 3.8.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41328029/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41328029/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter">Top 3 Tech And Telecom Stocks That Could Lead To Your Biggest Gains This Quarter</a></li>
</ul>

Eurozone

Commodities

Intraday Update

CDNA

ERIC

MGTX

PEGY

SEEL

WOLF

Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results

A wave of market-relevant news fueled an active trading session on Wall Street Tuesday, with large-cap indices falling due to sharp declines in tech and energy stocks, while small-caps outperformed, led by gains in regional banks.
At the forefront of the headlines is the massive plunge in ASML Holding NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) shares. The Dutch chipmaker&#8217;s stock nosedived over 16% after a technical error prematurely revealed its third-quarter earnings, originally scheduled for Wednesday, <a href="https://www.benzinga.com/markets/equities/24/10/41339229/asml-earnings-leak-sparks-broad-semiconductor-sell-off-sector-down-sharply-as-dutch-chipmaker-lo">on the company&#8217;s website. </a>
The report disclosed weaker-than-expected guidance for 2025, leading to the worst single-day drop in ASML stock since it went public in 2002.
ASML&#8217;s collapse sent shockwaves across the semiconductor sector, with the iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) falling more than 4%, marking its worst performance since early September. Key semiconductor players were hit hard, with NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) down 5% and Arm Holdings PLC-ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) tumbling 7%.
Another underperforming sector was energy. Oil prices plunged 5%, setting up their <a href="https://www.benzinga.com/markets/asia/24/10/41336413/oil-prices-take-largest-plunge-in-over-a-year-as-israel-vows-to-spare-iranian-facilities-energy-stoc">worst trading day in over a year. </a>
The sell-off followed a Monday&#8217;s report from The Washington Post, which revealed Israeli Prime Minister Benjamin Netanyahu assured the Biden administration Israel would refrain from targeting Iranian oil and nuclear facilities in any retaliatory military actions.
Meanwhile, the financial sector surged, extending its all-time highs as Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), and Charles Schwab Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) all posted <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41331839/financial-sector-hits-record-highs-as-goldman-sachs-bank-of-america-citi-beat-q3-ea">stronger-than-expected quarterly earnings.</a>
Gains also spread to more economically sensitive regional banks, with the SPDR S&amp;P Regional Banking ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>) jumping over 3%, lifting the broader Russell 2000 index by 1%.
In other markets, both the U.S. dollar and Treasury yields remained steady, as there were no major updates on interest-rate expectations. Gold edged up by 0.6%, while Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) continued its recent momentum, climbing 1.3% after a 5.1% surge on Monday.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg (1-day) %</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,272.05</td>
<td>1.0%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,942.79</td>
<td>-0.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,842.20</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,221.22</td>
<td>-1.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent101524&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.4% to $581.82.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;inched 0.3% down to $429.46.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 1.1% to $491.72.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1% to $222.52.</li>
<li>The Financials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) outperformed, up 1%. The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 2.3%.</li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
<ul>
<li>Airlines and cruise lines rallied in reaction to lower oil prices. American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) rose 2.2%, United Airlines Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) gained 2.2%. Carnival Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) and Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) rallied 7.7% and 5.5%, respectively. </li>
<li>Charles Schwab rose 7.5% after reporting stronger-than-expected quarterly results. </li>
<li>Other stocks reacting to earnings were UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), down 7.4%; Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), up 1.8%; Bank of America Corp., up 1.9%; Goldman Sachs Group Inc., down 0.3%; Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), down 4%; PNC Financial Services Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>), up 4%; State Street Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>), up 0.6% and Walgreens Boots Alliance Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>), up 13%</li>
<li>Companies slated to report earnings after the close include Interactive Brokers Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>), United Arlines Holdings Inc., Omnicon Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>) and J.B. Hunt Transport Services Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>). </li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41336897/3-reasons-why-a-bitcoin-all-time-high-before-the-election-is-back-in-play">3 Reasons Why A Bitcoin All-Time High Before The Election Is Back In Play</a></li>
</ul>
Photo: Shutterstock

Mid Cap

Sector ETFs

Broad U.S. Equity ETFs

Small Cap

Econ #s

Tech

ETFs

$BTC

ASML

SPDR Dow Jones Industrial Average ETF Trust

IBKR

JBHT

NCLH

NVDA

SCHW

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Chipmaker Stocks Sink On ASML Earnings Leak, Oil Eyes Worst 1-Day Drop This Year, Small Caps Rally: What's Driving Markets Tuesday?

To gain an edge, this is what you need to know today.
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2024/10/2024-10-15_08h50_10.png" alt="" style="width:624px" /></figure>
<h3 class="wp-block-heading">Google Goes Nuclear</h3>
Please <a href="https://thearorareport.com/chart-analysis-stock-market-israeli-restraint-google-nuclear-power-ai-nne-mc-10152024">click here</a> for an enlarged chart of Nano Nuclear Energy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>).
Note the following:
<ul>
<li>This article is about the big picture, not an individual stock. The chart of NNE is being used to illustrate the point.</li>
<li>NNE is a micro reactor company.</li>
<li>The trendline on the chart shows a steady uptrend since last month on the excitement about the use of nuclear power for AI data centers.</li>
<li>As full disclosure, there is a position in NNE in The Arora Report&#8217;s ZYX Buy Change Alert.</li>
<li>Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) has decided on nuclear power for AI data centers. Most importantly, Google has signed a Master Plant Development Agreement for smart modular reactors with Kairos Power. The first plant will be deployed by 2030.</li>
<li>The Google agreement will likely build more excitement for nuclear power. The Arora Report has previously mentioned three conventional nuclear plant operators: Constellation Energy Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>), Vistra Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>), and Public Service Enterprise Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>). There are two publicly traded smart modular reactors of note – Nuscale Power Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) and Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>).</li>
<li>There are reports Israel has told the U.S. that Israel will not attack Iran's nuclear facilities or oil infrastructure. This development is impacting the markets in the following ways:
<ul>
<li>Buying in stocks</li>
<li>Selling in volatility index (VIX) futures</li>
<li>Selling in the dollar</li>
<li>Selling in oil</li>
<li>Selling in gold and silver</li>
<li>As full disclosure, The Arora Report anticipated this scenario as the highest probability scenario and gave the following signals. Readers of The Arora Report got ahead of the curve when they received a signal to take partial profits on gold ETF SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) in The Arora Report&#8217;s ZYX Allocation as well as silver ETF SLV and gold miner Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) in The Arora Report&#8217;s ZYX Buy.</li>
</ul>
</li>
<li>Earnings season is in full swing.
<ul>
<li>Among important earnings of note, Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) and Goldman Sachs Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) reported earnings better than the consensus. As full disclosure, BAC is in The Arora Report&#8217;s ZYX Buy Core Model Portfolio and is long from $7.69. </li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) reported lower than expected earnings.</li>
<li>The nation's largest health insurer UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) is lowering its outlook due to rising medical costs.</li>
</ul>
</li>
</ul>
<h3 class="wp-block-heading">Magnificent Seven Money Flows</h3>
In the early trade, money flows are positive in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), GOOG, Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
In the early trade, money flows are neutral in NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
In the early trade, money flows are positive in SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
<h3 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h3>
Investors can gain an edge by knowing money flows in SPY and QQQ. Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil. The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>). The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>). The most popular ETF for oil is United States Oil ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>).
<h3 class="wp-block-heading">Bitcoin</h3>
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is range bound.
<h3 class="wp-block-heading">Protection Band And What To Do Now</h3>
It is important for investors to look ahead and not in the rearview mirror.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges. The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive. If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash. A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.  When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks. High beta stocks are the ones that move more than the market.
<h3 class="wp-block-heading">Traditional 60/40 Portfolio</h3>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less. Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

AAPL

AMZN

GOOG

MSFT

OKLO

TSLA

Google Goes Nuclear For AI Power, Israeli Restraint Impacts Stocks, Gold, And Oil

Tyra raised to buy by BofA ahead of TYRA-300 data readout

Income investors should focus on stocks with solid yields, sustainable payouts, and strong business models. One way to achieve this is by investing in safe dividend kings.

Three Safe Dividend Kings to Weather Any Storm

The FDA granted orphan designation to Janssen Research & Development's bleximenib as a treatment of acute myeloid leukemia, according to a post to ...

Johnson & Johnson treatment of acute myeloid leukemia granted orphan status

Activist investor Starboard takes stake in Kenvue - WSJ

Kenvue ($KVUE) is under pressure after activist investor Starboard Value acquired a stake in the company. According to the Wall Street Journal, the...

Kenvue (KVUE) Under Pressure after Activist Investor Starboard Acquires Stake

Activist hedge fund Starboard Value has reportedly taken a stake in Kenvue, sparking a pre-market stock surge.

Activist Investor Starboard Acquires Stake In Band-Aid Maker Kenvue, Shares Jump

Biggest stock movers Monday: LUMN, VFC, BA, SAVE, and more

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: The striking machinists at Boeing (BA)...

Boeing machinists announce proposal to end strike: Morning Buzz

Johnson & Johnson snaps six straight days of gains

Teva, Alvotech get expanded FDA approval for Stelara biosimilar

ALVO

BCSF

DRUG

GILD

GNTY

GOOS

LUMN

RLAY

ROAD

SAVE

SSNLF

TEVA

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

MRNA

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Opinion

Press Releases

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

Chicago Court Upholds $45 Million Mesothelioma Verdict Against Johnson & Johnson

Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference

Johnson & Johnson Completes Acquisition of V-Wave

TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis

Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference

Johnson & Johnson Reports Q3 2024 Results

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024

Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study

Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson

ANVS

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Johnson & Johnson

Johnson & Johnson (JNJ) Options

Johnson & Johnson (NYSE:JNJ) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL